Overview of Chirality and Chiral Drugs

Chiral Drugs: Chemistry and Biological Action

Volumn , Issue , 2011, Pages 3-28

  Lin, Guo Qiang ^a   Zhang, Jian Ge ^b   Cheng, Jie Fei ^c,d  

^a SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d Shanghai Veterinary Research Institute   (China)

Author keywords

Chiral industry, two categories chiral compound manufacture and chiral compound analysis; Chirality and chiral drugs pharmacological activity of drug, with biological matrices or drug targets; Chirality, property of three dimensional objects chiral drug, a chiral molecule with defined pharmaceutical pharmacological activities and utilities

Indexed keywords

EID: 84872511453     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118075647.ch1     Document Type: Chapter

References (79)

1. Piutti, A. (1886). Cristallographic Chimique-Sur une nouvelle espke d'asparagine. Compt. Rend. 103, 134-138.
2. Anonymous. (1962). Medicine: the thalidomide disaster. Time, August 10.
3. Blaschke, G., Kraft, H. P., Fickentscher, K., Kohler, F. (1979). Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers. Arzneimittelforschung 29, 1640-1642.
4. Fabro, S., Smith, R. L., Williams, R. T. (1967). Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215, 296-297.
5. Reist, M., Carrupt, P. A., Francotte, E., Testa, B. (1998). Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem. Res. Toxicol. 11, 1521-1528.
6. Eriksson, T., Bjorkman, S., Roth, B., Fyge, A., Hoglund, P. (1995). Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7, 44-52.
7. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, T., Yamaguchi, Y., Handa, H. (2010). Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350.
8. Lin, G. Q., Li, Y. M., Chen, A. S. C. (2001). Principles and Application of Asymmetric Synthesis. New York: Wiley-Interscience, p. 10, 17.
9. Rodger, A., Nordén, B. (1997). Circular Dichroism and Linear Dichroism. Oxford, UK: Oxford University Press, ISBN 019855897X.
10. Dale, J. A., Mosher, H. S. (1973). Nuclear magnetic resonance enantiomer regents. Configurational correlations via nuclear magnetic resonance chemical shifts of diastereomeric mandelate, O-methylmandelate, and alpha-methoxy-alpha-trifluoromethylphenylacetate (MTPA) esters. J. Am. Chem. Soc. 95, 512-519.
11. Ohtani, I., Kusumi, T., Kashman, Y, Kakisawa, H. (1991) High-field FT NMR application of Mosher's method. The absolute configurations of marine terpenoids. J. Am. Chem. Soc. 113, 4092-4096.
12. Seco, J. M., Quinoa, E., Riguera, R. (2004) The assignment of absolute configuration by NMR. Chem. Rev. 104, 17-117.
13. Hoye, T. R., Jeffrey, C. S., Shao, F. (2007) Mosher ester analysis for the determination of absolute configuration of stereogenic (chiral) carbinol carbons. Nat. Protoc. 2, 2451-2458.
14. Rothchild, R. (1989). Chiral lanthanide NMR shift reagents and equilibria with substrate enantiomers: rationale for the observed signals. J. Chem. Educ. 66, 814.
15. Knowles, W. S. (1983). Asymmetric hydrogenation. Acc. Chem. Res. 16, 106-112.
16. Miyashita, A., Yasuda, A., Takaya, H., Toriumi, K., Ito, T., Souchi T., Noyori, R. (1980). Synthesis of 2, 2'-bis(diphenylphosphino)-1, 1'-binaphthyl (BINAP), an atropisomeric chiral bis(triaryl)phosphine, and its use in the rhodium (I)-catalyzed asymmetric hydrogenation of a-(acylamino)acrylic acids. J. Am. Chem. Soc. 102, 7932-7934.
17. Hansen, K.B., Balsells, J., Dreher, S., Hsiao, Y., Kubryk, M., Palucki, M., Rivera, N., Steinhuebel, D., Armstrong, J. D. III, Askin, D., Grabowski, E. J. J. (2005). First generation process for the preparation of the DPP-IV inhibitor sitagliptin. Org. Process Res. Dev. 9, 634-639.
18. Katsuki, T., Sharpless, K.B. (1980). The 1st practical method for asymmetric epoxidation. J. Am. Chem. Soc. 102, 5974-5976.
19. Crabtree, R. H. (2009). Handbook of Green Chemistry, vol. 3 : Biocatalysis. Weinheim: Wiley-VCH, p. 173.
20. Broussy, S. B., Cheloha, R. W., Berkowitz, D. B. (2009). Enantioselective, ketoreductase-based entry into pharmaceutical building blocks: ethanol as tunable nicotinamide reductant. Org. Lett. 11, 305-308.
21. Patel, R., Hanson, R., Goswami, A., Nanduri, V., Banerjee, A., Donovan, M. J., Goldberg, S., Johnston, R., Brzozowski, D., Tully, T., Howell, J., Cazzulino, D., Ko, R. (2003). Enzymatic synthesis of chiral intermediates for pharmaceuticals. J. Ind. Microbiol. Biotechnol. 30, 252-259.
22. Drauz, K., Waldmann, H. (2004). Enzyme Catalysis in Organic Synthesis. Weinheim: Wiley-VCH, p. 151, 164.
23. Paquette, L. A. (2003) Handbook of Reagents for Organic Synthesis, Chiral Reagents for Asymmetric Synthesis. New York: Wiley, ISBN: 978-0-470-85625-3.
24. Ohkuma, T., Ooka, H., Hashiguchi, S., Ikariya, T., Noyori, R. (1995). Practical enantioselective hydrogenation of aromatic ketones. J. Am. Chem. Soc. 117, 2675-2676.
25. Thayer. A. M. (2007). Centering on chirality. Chem. Eng. News, 85, 11-19.
26. List, B. (2007). Introduction: organocatalysis. Chem. Rev. 107, 5413-5415.
27. MacMillan, D. W. C. (2008). The advent and development of organocatalysis. Nature 455, 304-308.
28. Akiyama, T. (2007). Stronger Brønsted acids. Chem. Rev. 107, 5744-5758.
29. Doyle, A. G., Jacobsen, E. N. (2007). Small-molecule H-bond donors in asymmetric catalysis. Chem. Rev. 107, 5713-5743.
30. Hajos, Z. G., Parrish, D. R. (1971). DE 2102623.
31. Hajos, Z. G., Parrish, D.R. (1974). Asymmetric synthesis of bicyclic intermediates of natural product chemistry. J. Org. Chem. 39, 1615-1621.
32. Deer, U., Sauer, G., Wiechert, R. (1971). DE 2014757.
33. Eder, U., Sauer, G., Wiechert, R. (1971). New type of asymmetric cyclization to optically active steroid CD partial structures. Angew. Chem. Int. Ed. Engl. 10, 496-497.
34. MacMillan, D. W. C. (2008). The advent and development of organocatalysis. Nature 455, 304-308.
35. Houk, K. N., List, B. (2004). Asymmetric organocatalysis. Acc. Chem. Res. 37, 487-621.
36. Kocovsky, P., Malkov, A. V. (2006). Organocatalysis in organic synthesis. Tetrahedron 62, 255.
37. List, B. (2007). Introduction: organocatalysis. Chem. Rev. 107, 5413-5883.
38. Berkessel, A., Gröger, H. G. (2005). Asymmetric Organocatalysis: From Biomimetic Concepts to Application in Asymmetric Synthesis. Weinheim: Wiley-VCH, p. 1, 2.
39. Seki, M. (2008). A practical synthesis of a key chiral drug intermediate via asymmetric organocatalysis. Synlett 2, 164-176.
40. Patil, P. A., Kothekar, M. A. (2006). Development of safer molecules through chirality. Indian. J. Med. Sci 60, 427-437.
41. McConathy J., Owens, M. J. (2003). Stereochemistry in drug action. Primary Care Companion J Clin. Psychiatry 5, 70-73.
42. Tenero, D., Boike, S., Boyle, D., Ilson, B., Fesniak, H. F., Brozena, S., Jorkasky, D. (2000). Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J. Clin. Pharmacol. 40, 844-853.
43. Bartsch, W., Sponer, G., Strein, K., Müller-Beckmann, B., Kling, L., Böhm, E., Martin, U., Borbe, H. O. (1990). Pharmacological characteristics of the stereoisomers of carvedilol. Eur. J. Clin. Pharmacol. 38, S104-S107.
44. Mehvar, R., Brocks, D. R. (2001). Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J. Pharm. Pharm. Sci. 4, 185-200.
45. Krogsgaard-Larsen, P., Liljefors, T., Madsen, U. (2002). Textbook of Drug Design and Discovery. New York: Taylor and Francis, p. 56.
46. Hollister, L. E., Gillespie, H. K., Mechoulam, R., Srebnik. M. (1987). Human pharmacology of 1S and 1R enantiomers of delta-3-tetrahydrocannabinol. Psychopharmacology 92, 505-507.
47. Leffingwell, J. C. (2003). Chirality & bioactivity I: pharmacology. Leffingwell Rep. 3, 1-27.
48. Salunkhe, M. M., Nair, R. V. (2001). Novel route for the resolution of both enantiomers of dropropizine by using oxime esters and supported lipases of Pseudomonas capacia. Enzyme. Microb. Technol. 28, 333-338.
49. Sacerdote, P., Bianchi, M., Gaspani, L., Panerai, A. E. (1999). Effects of tramadol and its enantiomers on Concanavalin-A induced-proliferation and NK activity of mouse splenocytes: involvement of serotonin. Int. J. Immunopharmacol. 21, 727-734.
50. Rojas-Corrales, M. O., Giber-t-Rahola, J., Mica, J. A. (1998). Tramadol induces antidepressant-type effects in mice. Life Sci. 63, 175-180.
51. Leffingwell, J. C. (2003). Chirality & bioactivity I: pharmacology. Leffingwell Rep. 3, 1-27.
52. Fokkens, J., Klebe, G. (2006). A simple protocol to estimate differences in protein binding affinity for enantiomers without prior resolution of racemates. Angew. Chem. Int. Ed. 45, 985-989.
53. Thurkauf, A., Hillery, P., Mattson, M. V., Jacobson, A. E., Rice, K. C. (1988). Synthesis, pharmacological action, and receptor binding affinity of the enantiomeric 1-(1-phenyl-3-methylcyclohexyl) piperidines. J. Med. Chem. 31, 1625-1628.
54. Pfeiffer, C. C. (1956). Optical isomerism and pharmacological action, a generalization. Science 124, 29-31.
55. Seri Levy, A., Richards, W. G. (1993). Chiral drug potency: Pfeiffer's rule and computed chirality coefficients. Tetrahedron Asym. 4, 1917-1923.
56. Koldsø, H., Severinsen, K., Tran, T. T., Celik, L., Jensen, H. H., Wiborg, O., Schiøtt, B., Sinning, S. (2010). The two enantiomers of citalopram bind to the human serotonin transporter in reversed orientations. J. Am. Chem. Soc. 132, 1311-1322.
57. Brocks, D. R. (2006). Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharm. Drug Dispos. 27, 387-406.
58. Lane, R. M., Baker, G. B. (1999). Chirality and drugs used in psychiatry: nice to know or need to know? Cell Mol. Neurobiol. 19, 355-372.
59. Foster, D. J. R., Somogyi, A. A., Dyer, K. R., White, J. M., Bochner. F. Br. (2000). Steady-state pharmacokinetics of (R)-and (S)-methadone in methadone maintenance patients. J. Clin. Pharmacol. 50, 427-440.
60. Baumann, P., Zullino, D. F., Eap, C. B. (2002). Enantiomers' potential in psychopharmacology-a critical analysis with special emphasis on the antidepressant escitalopram. Eur. Neuropsychopharmacol. 12, 433-444.
61. Andersson, T., Weidolf, L. (2008). Stereoselective disposition of proton pump inhibitors. Clin. Drug. Invest. 28, 263-279.
62. Gillard, M., Van Der Perren, C., Moguilevsky, N., Massingham, R., Chatelain, P. (2002). Binding characteristics of cetirizine and levocetirizine to human H1 histamine receptors: contribution of Lys191 and Thr194. Mol. Pharmacol. 61, 391-399.
63. Tillementa, J. P., Testab, B., Brée. F. (2003). Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem. Pharmacol. 66, 1123-1126.
64. Eap, C. B., Bender, S., Gastpar, M., Fischer, W., Haarmann, C., Powell, K., Jonzier-Perey, M., Cochard, N., Baumann, P. (2000). Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients. Ther. Drug. Monit. 22, 209-214.
65. Web site addresses for regulatory agencies: http://www.hc-sc.gc.ca/hpb/Canada;http://www.ifpma.org/ich1.htmlICH;http://www.mhw.go.jp/english/index.htmlJapan;http://www.health.gov.au/tga/Australia;http://eudraportal.eudra.org/EMEA.
66. Shindo, H., Caldwell, J. (1995). Development of chiral drugs in Japan: an update on regulatory and industrial opinion. Chirality 7, 349-352.
67. Shimazawa, R., Nagai, N., Toyoshima, S., Okuda, H. (2008). Present status of new chiral drug development and review in Japan. J. Health Sci. 54, 23-29.
68. FDA's policy statement for the development of new stereoisomeric drugs. (1992). Chirality, 4, 338-340.
69. Branch, S. (2001). International regulation of chiral drugs. In: Chiral Separation Techniques. A. Practical Approach. 2nd Edition, Subramanian, G., editor. Weinheim: Wiley-VCH, p. 319-342.
70. Huang, Z. W. (2007). Drug Discovery Research: New Frontiers in the Post-Genomic Era. Hoboken, NJ: John Wiley & Sons, Inc., p. 243.
71. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/chem/stereoeng. php.
72. Caner, H., Groner, E., Levy, L., Agranat I. (2004). Trends in the development of chiral drugs. Drug Discov. Today 9, 105-110.
73. Agranat, I., Caner, H., Caldwell, J. (2002). Putting chirality to work: the strategy of chiral switches. Nat. Rev. Drug. Discov. 1, 753-768.
74. Maier, N. M., Franco, P., Lindner, W. (2001). Separation of enantiomers: needs, challenges, perspectives. J. Chromatograph. A. 906, 3-33.
75. Agranat, I., Caner, H., Caldwell, J. (2002). Putting Chirality to work: the strategy of chiral switches. Nat. Rev. Drug Discov. 1, 753-768.
76. Tucker, G. (2000). Chiral switches. Lancet 355, 1085-1087.
77. Erb, S. (2006). Single-enantiomer drugs poised for further market growth. Pharmaceut. Technol. 30, ps14-s18.
78. Van Arnum, P. (2006). Single-enantiomer drugs drive advances in asymmetric synthesis (cover story). Pharmaceut. Technol. 30, 58-66.
79. Anonymous. (2009). Annual Report inMedicinal Chemistry, 1992-2009, Vol. 27-44.